A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma

J. P. Leonard, J. W. Friedberg, A. Younes, D. Fisher, L. I. Gordon, J. Moore, M. Czuczman, Thomas P Miller, P. Stiff, B. D. Cheson, A. Forero-Torres, N. Chieffo, B. McKinney, D. Finucane, A. Molina

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

Background: Galiximab is a monoclonal antibody that targets CD80, a costimulatory molecule constitutively expressed on follicular and other lymphomas. Modest single-agent clinical activity and tolerability were demonstrated in a phase I study in relapsed or refractory, follicular non-Hodgkin's lymphoma (NHL). A phase I/II study was conducted to evaluate galiximab in combination with a standard course of rituximab. Safety, pharmacokinetics, and efficacy were evaluated. Patients and methods: Patients with follicular NHL who had relapsed or failed primary therapy were enrolled. Rituximab-refractory patients (no response or a response with time to progression <6 months) were excluded. Patients received 4 weekly i.v. infusions of galiximab (125, 250, 375, or 500 mg/m2) and rituximab (375 mg/m2). International Workshop Response Criteria (IWRC) were used to evaluate response. Results: Seventy-three patients received treatment. All had received at least one prior lymphoma therapy; 40% were rituximab naive. Infusions were delivered in an outpatient setting and were well tolerated. The most common study-related adverse events (AE) were lymphopenia, leukopenia, neutropenia, fatigue, and chills. The overall response rate at the recommended phase II dose of galiximab (500 mg/m2) was 66%: 19% complete response, 14% unconfirmed complete response, and 33% partial response. The median progression free survival was 12.1 months. Combination therapy did not appear to alter pharmacokinetics. Conclusion: These results indicate that galiximab can be safely combined with a standard course of rituximab. This doublet biologic approach offers the potential to avoid or delay chemotherapy or to integrate with other lymphoma therapies. A phase III, randomized study evaluating clinical benefit of rituximab versus the combination has been initiated.

Original languageEnglish (US)
Pages (from-to)1216-1223
Number of pages8
JournalAnnals of Oncology
Volume18
Issue number7
DOIs
StatePublished - Jul 2007

Fingerprint

Follicular Lymphoma
Monoclonal Antibodies
Non-Hodgkin's Lymphoma
Lymphoma
Pharmacokinetics
Therapeutics
Chills
Lymphopenia
Leukopenia
Neutropenia
Disease-Free Survival
Fatigue
galiximab
Rituximab
Outpatients
Safety
Education
Drug Therapy

Keywords

  • CD80
  • Galiximab
  • Lymphoma
  • Monoclonal antibody
  • Rituximab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. / Leonard, J. P.; Friedberg, J. W.; Younes, A.; Fisher, D.; Gordon, L. I.; Moore, J.; Czuczman, M.; Miller, Thomas P; Stiff, P.; Cheson, B. D.; Forero-Torres, A.; Chieffo, N.; McKinney, B.; Finucane, D.; Molina, A.

In: Annals of Oncology, Vol. 18, No. 7, 07.2007, p. 1216-1223.

Research output: Contribution to journalArticle

Leonard, JP, Friedberg, JW, Younes, A, Fisher, D, Gordon, LI, Moore, J, Czuczman, M, Miller, TP, Stiff, P, Cheson, BD, Forero-Torres, A, Chieffo, N, McKinney, B, Finucane, D & Molina, A 2007, 'A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma', Annals of Oncology, vol. 18, no. 7, pp. 1216-1223. https://doi.org/10.1093/annonc/mdm114
Leonard, J. P. ; Friedberg, J. W. ; Younes, A. ; Fisher, D. ; Gordon, L. I. ; Moore, J. ; Czuczman, M. ; Miller, Thomas P ; Stiff, P. ; Cheson, B. D. ; Forero-Torres, A. ; Chieffo, N. ; McKinney, B. ; Finucane, D. ; Molina, A. / A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. In: Annals of Oncology. 2007 ; Vol. 18, No. 7. pp. 1216-1223.
@article{ec60a460fd75410e854ec456416070a9,
title = "A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma",
abstract = "Background: Galiximab is a monoclonal antibody that targets CD80, a costimulatory molecule constitutively expressed on follicular and other lymphomas. Modest single-agent clinical activity and tolerability were demonstrated in a phase I study in relapsed or refractory, follicular non-Hodgkin's lymphoma (NHL). A phase I/II study was conducted to evaluate galiximab in combination with a standard course of rituximab. Safety, pharmacokinetics, and efficacy were evaluated. Patients and methods: Patients with follicular NHL who had relapsed or failed primary therapy were enrolled. Rituximab-refractory patients (no response or a response with time to progression <6 months) were excluded. Patients received 4 weekly i.v. infusions of galiximab (125, 250, 375, or 500 mg/m2) and rituximab (375 mg/m2). International Workshop Response Criteria (IWRC) were used to evaluate response. Results: Seventy-three patients received treatment. All had received at least one prior lymphoma therapy; 40{\%} were rituximab naive. Infusions were delivered in an outpatient setting and were well tolerated. The most common study-related adverse events (AE) were lymphopenia, leukopenia, neutropenia, fatigue, and chills. The overall response rate at the recommended phase II dose of galiximab (500 mg/m2) was 66{\%}: 19{\%} complete response, 14{\%} unconfirmed complete response, and 33{\%} partial response. The median progression free survival was 12.1 months. Combination therapy did not appear to alter pharmacokinetics. Conclusion: These results indicate that galiximab can be safely combined with a standard course of rituximab. This doublet biologic approach offers the potential to avoid or delay chemotherapy or to integrate with other lymphoma therapies. A phase III, randomized study evaluating clinical benefit of rituximab versus the combination has been initiated.",
keywords = "CD80, Galiximab, Lymphoma, Monoclonal antibody, Rituximab",
author = "Leonard, {J. P.} and Friedberg, {J. W.} and A. Younes and D. Fisher and Gordon, {L. I.} and J. Moore and M. Czuczman and Miller, {Thomas P} and P. Stiff and Cheson, {B. D.} and A. Forero-Torres and N. Chieffo and B. McKinney and D. Finucane and A. Molina",
year = "2007",
month = "7",
doi = "10.1093/annonc/mdm114",
language = "English (US)",
volume = "18",
pages = "1216--1223",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma

AU - Leonard, J. P.

AU - Friedberg, J. W.

AU - Younes, A.

AU - Fisher, D.

AU - Gordon, L. I.

AU - Moore, J.

AU - Czuczman, M.

AU - Miller, Thomas P

AU - Stiff, P.

AU - Cheson, B. D.

AU - Forero-Torres, A.

AU - Chieffo, N.

AU - McKinney, B.

AU - Finucane, D.

AU - Molina, A.

PY - 2007/7

Y1 - 2007/7

N2 - Background: Galiximab is a monoclonal antibody that targets CD80, a costimulatory molecule constitutively expressed on follicular and other lymphomas. Modest single-agent clinical activity and tolerability were demonstrated in a phase I study in relapsed or refractory, follicular non-Hodgkin's lymphoma (NHL). A phase I/II study was conducted to evaluate galiximab in combination with a standard course of rituximab. Safety, pharmacokinetics, and efficacy were evaluated. Patients and methods: Patients with follicular NHL who had relapsed or failed primary therapy were enrolled. Rituximab-refractory patients (no response or a response with time to progression <6 months) were excluded. Patients received 4 weekly i.v. infusions of galiximab (125, 250, 375, or 500 mg/m2) and rituximab (375 mg/m2). International Workshop Response Criteria (IWRC) were used to evaluate response. Results: Seventy-three patients received treatment. All had received at least one prior lymphoma therapy; 40% were rituximab naive. Infusions were delivered in an outpatient setting and were well tolerated. The most common study-related adverse events (AE) were lymphopenia, leukopenia, neutropenia, fatigue, and chills. The overall response rate at the recommended phase II dose of galiximab (500 mg/m2) was 66%: 19% complete response, 14% unconfirmed complete response, and 33% partial response. The median progression free survival was 12.1 months. Combination therapy did not appear to alter pharmacokinetics. Conclusion: These results indicate that galiximab can be safely combined with a standard course of rituximab. This doublet biologic approach offers the potential to avoid or delay chemotherapy or to integrate with other lymphoma therapies. A phase III, randomized study evaluating clinical benefit of rituximab versus the combination has been initiated.

AB - Background: Galiximab is a monoclonal antibody that targets CD80, a costimulatory molecule constitutively expressed on follicular and other lymphomas. Modest single-agent clinical activity and tolerability were demonstrated in a phase I study in relapsed or refractory, follicular non-Hodgkin's lymphoma (NHL). A phase I/II study was conducted to evaluate galiximab in combination with a standard course of rituximab. Safety, pharmacokinetics, and efficacy were evaluated. Patients and methods: Patients with follicular NHL who had relapsed or failed primary therapy were enrolled. Rituximab-refractory patients (no response or a response with time to progression <6 months) were excluded. Patients received 4 weekly i.v. infusions of galiximab (125, 250, 375, or 500 mg/m2) and rituximab (375 mg/m2). International Workshop Response Criteria (IWRC) were used to evaluate response. Results: Seventy-three patients received treatment. All had received at least one prior lymphoma therapy; 40% were rituximab naive. Infusions were delivered in an outpatient setting and were well tolerated. The most common study-related adverse events (AE) were lymphopenia, leukopenia, neutropenia, fatigue, and chills. The overall response rate at the recommended phase II dose of galiximab (500 mg/m2) was 66%: 19% complete response, 14% unconfirmed complete response, and 33% partial response. The median progression free survival was 12.1 months. Combination therapy did not appear to alter pharmacokinetics. Conclusion: These results indicate that galiximab can be safely combined with a standard course of rituximab. This doublet biologic approach offers the potential to avoid or delay chemotherapy or to integrate with other lymphoma therapies. A phase III, randomized study evaluating clinical benefit of rituximab versus the combination has been initiated.

KW - CD80

KW - Galiximab

KW - Lymphoma

KW - Monoclonal antibody

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=34547844167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547844167&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdm114

DO - 10.1093/annonc/mdm114

M3 - Article

C2 - 17470451

AN - SCOPUS:34547844167

VL - 18

SP - 1216

EP - 1223

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 7

ER -